Pregled bibliografske jedinice broj: 549585
PERFORMANCE EVALUATION OF THE ROCHE ELECSYS PAPP-A AND FREE BETA HCG SCREENING ASSAYS
PERFORMANCE EVALUATION OF THE ROCHE ELECSYS PAPP-A AND FREE BETA HCG SCREENING ASSAYS // IFCC–WorldLab-EuroMedLab Berlin 2011
Berlin, Njemačka: Clinical Chemistry and Laboratory Medicine Berlin, New York: Walter de Gruyter, 2011. str. 696-696 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 549585 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PERFORMANCE EVALUATION OF THE ROCHE ELECSYS PAPP-A AND FREE BETA HCG SCREENING ASSAYS
Autori
Flegar-Meštrić, Zlata ; Šimonović, Barbara
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
IFCC–WorldLab-EuroMedLab Berlin 2011
/ - : Clinical Chemistry and Laboratory Medicine Berlin, New York: Walter de Gruyter, 2011, 696-696
Skup
IFCC–WorldLab-EuroMedLab Berlin 2011
Mjesto i datum
Berlin, Njemačka, 15.05.2011. - 19.05.2011
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Down syndrome screening; Roche Elecsys screening assays pregnancy-associated plasma protein-A (PAPP-A); maternal serum free beta-human chorionic gonadotropin (beta-hCG)
Sažetak
Background. Routine first trimester Down syndrome screening supports an earlier decision-making process and helps to ensure safer pregnancies. We evaluated the performance characteristics of Roche Elecsys screening assays pregnancy-associated plasma protein-A (PAPP-A) and maternal serum free beta-human chorionic gonadotropin (beta-hCG). Methods. PAPP-A and free beta hCG concentrations were measured by electrochemiluminescent (ECL) technology on Roche Elecsys analyzer. Verification of performance for precision was performed based on guidance from the Clinical and Laboratory Standards Institute (CLSI) Document EP15-A2. Participation in the United Kingdom National External Quality Assessment Service (UKNEQAS) scheme for First Trimester Downs Syndrome Screening on monthly basis allowed us to monitor long-term analytical bias and risks calculations for trisomy 21 and 18/13 using SsdwLab 5.0.9 software approved by the Fetal Medicine Foundation. Results. The within-laboratory precision obtained for PAPP-A assay was 2.0% and 2.1% in the low and high concentration level, respectively and 2.7% and 3.3% for free beta hCG measurements, respectively. Expanded measurement uncertainties were ±8.6% and ±7.8% (k=2 representing a confidence level of 95%) in the low and high concentration level for PAPP-A assay and ±6.4% and ±6.8% for free beta hCG measurements, respectively. The long-term results in the UKNEQAS scheme showed acceptable performance with the analytical bias from the method mean within 10% for both assays. Conclusions. The Roche Elecsys serum PAPP-A and free beta hCG assays ensure reliable analytical results with method target values that fall within Fetal Medicine Foundation accreditation targets.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE